Q2 saw 29% revenue growth and a 35% adjusted EBITA margin, driven by strong performance across all regions and key products like ALTUVOCT, Doptelet, and Gamifant. The outlook for 2026 was raised, with continued pipeline progress and new launches supporting long-term growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.